Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics ...
Korro Bio’s Promising Regulatory and Preclinical Advances Earn a Buy Rating from Analyst Mitchell Kapoor
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Yahoo Finance5d
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...
Investing1d
4 Biotech Stocks With AI, Machine Learning Prowess
Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Fintel on MSN19d
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation
Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...
Investing22d
Korro Bio shares target lifted, buy rating on RNA editing potential
On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock.
ETF Daily News18d
Korro Bio (NASDAQ:KRRO) Price Target Raised to $105.00
Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...
Investing16d
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap
Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...
Investing22d
Korro Bio shares target lifted, buy rating on RNA editing potential
On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock. The firm's ...